Monalizumab

Last updated
Monalizumab
Monoclonal antibody
Type ?
Source Humanized
Target NKG2A
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII

Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies [1] and other cancers. [2] [3]

Mechanism of action

Monalizumab is a monoclonal antibody targeted at NKG2A. [4] It is a checkpoint inhibitor. [5] [6]

References

  1. ↑ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
  2. ↑ IPH2201 studies
  3. ↑ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
  4. ↑ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
  5. ↑ "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
  6. ↑ van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1): 263. doi: 10.1186/s40425-019-0761-3 . PMC   6798508 . PMID   31623687.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.